Clair is building life stage intelligence.
What’s happening: The Stanford-born startup is developing a noninvasive continuous hormonal health monitor, delivering preventative insights for women from first period through menopause.
Life alert. Packing 10 biosensors into a wrist-worn device—which ships in November—Clair uses AI to triangulate skin temp, heart rate, HRV, breath rate, electrodermal activity, and sleep data for estimates on estrogen, progesterone, LH, and FSH in real time.
Following women across life stages, Clair aims to surface proactive signals spanning fertility tracking, athletic performance, and perimenopause. Trained on diverse physiological data, the company claims it addresses a long-standing a blind spot — maintaining accuracy even for women with PCOS and irregular periods.
In sync. While fertility and midlife care platforms fill healthcare gaps, women want daily intel on dynamic changes influencing energy, performance, and more.
Turning to tech, the race for true continuous hormone monitoring is in high gear, with urine and saliva tests turning instant results into personalized advice and incumbent wearables decoding perimenopausal changes.
Punchline: Creating a category, hormone-specific devices like Clair, Peri, and Level Zero will need to prove clinical efficacy and actionability to justify another wearable.
